A Randomized Controlled Trial of Metacognitive Therapy and EMDR for Posttraumatic Stress Disorder
Posttraumatic Stress Disorder
About this trial
This is an interventional treatment trial for Posttraumatic Stress Disorder focused on measuring Metacognitive therapy, Eye Movement Desensitization Reprocessing (EMDR), Cognitive therapy
Eligibility Criteria
Inclusion Criteria:
- a primary diagnosis of PTSD according to the Anxiety Disorders Interview Schedule (ADIS-IV)
- not previously received EMDR or MCT for this diagnosis
- not actively suicidal, presenting with suicidal ideation, psychotic or suffering from severe depression
- no evidence of alcohol or drug dependence
- Symptom chronicity of >3 months post-trauma
Exclusion Criteria:
- PTSD is not the primary diagnosis
- expressing suicidal ideation, actively psychotic, or engaging in overt self-harm
- Evidence of alcohol or drug dependence requiring treatment in its own right
- Borderline personality disorder
- Symptom chronicity <3 months post-trauma
- no ability to understand or speak Norwegian
Sites / Locations
- Outpatient speciality clinic for PTSD and other trauma-related emotional disorders at Østmarka, St. Olav University Hospital
Arms of the Study
Arm 1
Arm 2
Arm 3
Experimental
Active Comparator
Active Comparator
Metacognitive therapy
EMDR
Treatment as usual
The focus of metacognitive therapy (MCT) is on metacognitive beliefs thought to underlie the development and maintenance of posttraumatic symptomatology.
Eye movement desensitization reprocessing (EMDR): participant is asked to focus on trauma-related imagery, negative cognitions and body sensations while simultaneously focusing attention to a bilateral physical stimulation.
A group of 30 patients matched for age, gender and personality disorders receiving treatment as usual (TaU) in an outpatient setting will be included as a non-randomized comparative control condition.